Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn Sells 604 Shares

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 604 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total value of $16,295.92. Following the sale, the senior vice president now owns 115,029 shares of the company’s stock, valued at approximately $3,103,482.42. This represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Monday, January 6th, Amy Beth Vanduyn sold 1,311 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71.
• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total transaction of $532,605.71.

Phreesia Trading Up 1.6 %

Phreesia stock traded up $0.44 during trading hours on Friday, reaching $27.24. The stock had a trading volume of 309,924 shares, compared to its average volume of 382,284. The stock has a market cap of $1.58 billion, a PE ratio of -18.53 and a beta of 0.94. The company has a fifty day simple moving average of $23.42 and a 200-day simple moving average of $22.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same period in the prior year, the firm earned ($0.58) earnings per share. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. Analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Trust Point Inc. lifted its position in Phreesia by 3.5% during the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after purchasing an additional 607 shares during the period. Ensign Peak Advisors Inc lifted its position in Phreesia by 3.2% during the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock valued at $477,000 after purchasing an additional 700 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after purchasing an additional 853 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in shares of Phreesia by 3.8% during the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after buying an additional 1,120 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PHR shares. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Citigroup raised their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. KeyCorp boosted their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Finally, JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Phreesia has a consensus rating of “Buy” and a consensus price target of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.